First human test of Pfizer's new cancer drug halted
NCT ID NCT05233436
Summary
This early-stage study aimed to test the safety and find the right dose of a new drug, PF-07265028, for people with advanced cancers that have spread. The drug was tested alone and in combination with another cancer therapy called sasanlimab. The trial was terminated after enrolling 21 participants with various advanced solid tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
HonorHealth Scottsdale Shea Medical Center
Scottsdale, Arizona, 85260, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
The Cancer Institute Hospital of JFCR
Koto, Tokyo, 135-8550, Japan
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.